GlaxoSmithKline (GSK) has announced the impending discontinuation of its DTaP-IPV vaccine, Infanrix-IPV. The vaccine combines diphtheria, tetanus, and acellular pertussis vaccine (also known as DTaP) with an inactivated poliovirus vaccine (also known as IPV).

The pharmaceutical company reported this decision to the Ministry of Food and Drug Safety on Monday.

Infanrix-IPV is a vaccine included in the National Immunization Program (NIP) and is administered to infants and young children from the age of two months for the prevention of diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio).

The NIP supports essential vaccinations designated by the government, covering the cost when administered at public health centers and designated medical institutions.

The vaccine is given in three doses of 0.5 mL each at 2, 4, and 6 months of age, followed by a booster dose of 0.5 mL at 4 to 6 years of age.

GSK anticipates that the current stockpile will be depleted by Jan.1, 2025.

"The discontinuation of Infanrix-IPV in the Korean market is due to the availability of alternative treatments and is part of our business optimization strategy," a GSK spokesperson told Korea Biomedical Review. "This decision is aimed at providing a better treatment environment for more patients and healthcare professionals through a diverse range of therapeutic options."

GSK Korea remains committed to disease prevention, adapting to market changes, and striving to improve the lives of many patients in Korea, she added.

When asked about the potential resumption of supply, GSK did not provide a specific timeline but reassured that its ongoing dedication to disease prevention and market adaptability to serve patients better.